Insight Molecular Diagnostics (IMDX) Cost of Revenue (2020 - 2026)

Insight Molecular Diagnostics has reported Cost of Revenue for 7 years, with the latest figure at $17000.0 in Q1 2026.

• Quarterly Cost of Revenue fell 97.91% year-over-year to $17000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $949000.0 (down 45.99% YoY) and the FY2025 annual result came in at $1.8 million, up 66.19% from the prior year.
• Cost of Revenue slipped to $17000.0 in Q1 2026 per IMDX's latest filing, from $643000.0 in the prior quarter.
• Over five years, Cost of Revenue peaked at $2.1 million in Q4 2022 and troughed at $17000.0 in Q1 2026.
• A 5-year average of $483176.5 and a median of $183000.0 in 2022 frame the typical range for Cost of Revenue.
• The sharpest annual moves came in 2025 and 2026: Cost of Revenue surged 645.87% in 2025, then tumbled 97.91% in 2026.
• Over 5 years, Cost of Revenue stood at $2.1 million in 2022, then sank by 80.3% to $409000.0 in 2023, then jumped by 112.47% to $869000.0 in 2024, then slipped by 26.01% to $643000.0 in 2025, then tumbled by 97.36% to $17000.0 in 2026.
• According to Business Quant data, Cost of Revenue over the past three periods registered $17000.0, $643000.0, and $121000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.